{"id":751166,"date":"2023-04-25T18:42:25","date_gmt":"2023-04-25T22:42:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"modified":"2023-04-25T18:42:25","modified_gmt":"2023-04-25T22:42:25","slug":"achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","title":{"rendered":"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement"},"content":{"rendered":"<h2>\nAchilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company\u2019s operations are not affected by the receipt of the Notice<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">LONDON, April  25, 2023  (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company\u2019s American Depositary Shares (the \u201cADS\u201d) on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Requirement\u201d). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until October 18, 2023 (the \u201cCompliance Deadline\u201d), to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Company\u2019s ADSs meet or exceed $1.00 per ADS for at least ten consecutive business days.<\/p>\n<p align=\"justify\">The Nasdaq deficiency letter has no immediate effect on the listing of the Company\u2019s ADSs, and its ADSs will continue to trade on The Nasdaq Global Select Market under the symbol \u201cACHL\u201d at this time. The Company intends to monitor the closing bid price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance by the Compliance Deadline, the Company may be afforded an additional 180 calendar day period to regain compliance.<\/p>\n<p>\n        <strong>About Achilles Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I\/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS\u2122 bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains express or implied forward-looking statements that are based on our management&#8217;s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Lee M. Stern<br \/>VP, IR &amp; External Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mZJVydo6jHYxSAldGPQTI9gfqwe3vT1Ry_R93dFKb9nsllmsiImmYr0WLxfJcu8lSRpE4AkyPQ4pa65YrF0xMw==\" rel=\"nofollow noopener\" target=\"_blank\">ir@achillestx.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Consilium Strategic Communications<br \/>Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner<br \/>+44 (0) 203 709 5000<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hr1Ppbfr7Nuz79D2L3OJCEcRV1DZ-kprnlrGjapa89OS20cu6yV9sNiM6-oPnJfj-cbzuHU6ma2j3LbmusmZV7oNlWWfBn2HUUqYT7G-nRcOOzSn8vCnb0JnfNcXP7q2\" rel=\"nofollow noopener\" target=\"_blank\">achillestx@consilium-comms.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MzUxNmQ4MjMtYmQ2NS00MDE1LWE3ZmUtMWEzNGY5MDc4OTUwLTEyMTgyOTg=\/tiny\/Achilles-Therapeutics-PLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company\u2019s operations are not affected by the receipt of the Notice LONDON, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company\u2019s American Depositary Shares (the \u201cADS\u201d) on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Requirement\u201d). &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751166","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company\u2019s operations are not affected by the receipt of the Notice LONDON, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company\u2019s American Depositary Shares (the \u201cADS\u201d) on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Requirement\u201d). &hellip; Continue reading &quot;Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T22:42:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement\",\"datePublished\":\"2023-04-25T22:42:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\"},\"wordCount\":575,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\",\"name\":\"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=\",\"datePublished\":\"2023-04-25T22:42:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","og_description":"Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company\u2019s operations are not affected by the receipt of the Notice LONDON, April 25, 2023 (GLOBE NEWSWIRE) &#8212; Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (\u201cNasdaq\u201d) that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company\u2019s American Depositary Shares (the \u201cADS\u201d) on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the \u201cMinimum Bid Price Requirement\u201d). &hellip; Continue reading \"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T22:42:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement","datePublished":"2023-04-25T22:42:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"},"wordCount":575,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/","name":"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=","datePublished":"2023-04-25T22:42:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNTM3NCM1NTU2ODQ1IzIyMDY3NDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751166"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751166\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}